Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 57 articles: HTML format

Single Articles

December 2025
1. KU AT, Shankavaram U, Trostel SY, Zhang H, et al
   Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-beta Activity Driving Tumor Recurrence.
   Clin Cancer Res. 2025;31:5211-5224.
   PubMed     Abstract available
   
   
   
2. SAYEGH N, Graf RP, Swami U, Ozay ZI, et al
   Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.
   Clin Cancer Res. 2025 Dec 4. doi: 10.1158/1078-0432.CCR-25-2750.
   PubMed     Abstract available
   
   
   
3. MEDINA S, Tokuyama N, Hammouda K, Pathak T, et al
   A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.
   Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-3327.
   PubMed     Abstract available
   
   
   
4. MORRIS MJ, Flynn J, Zhao B, Anand A, et al
   Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancer.
   Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-2890.
   PubMed     Abstract available
   
   
   November 2025
5. MCHUGH D, Dallos M, Teo MY, McBride SM, et al
   Accelerating Drug Development in Hormone-Naive Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
   Clin Cancer Res. 2025 Nov 20. doi: 10.1158/1078-0432.CCR-25-2679.
   PubMed     Abstract available
   
   
   October 2025
6. NYQUIST MD, Nelson P
   Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle.
   Clin Cancer Res. 2025 Oct 29. doi: 10.1158/1078-0432.CCR-25-3045.
   PubMed     Abstract available
   
   
   
7. BOUZAKI A, Vasquez Osorio E, Kerns S, van Herk M, et al
   Integration of dose surface maps and genetic data identifies the lower posterior rectum as a key region for toxicity after prostate cancer radiotherapy.
   Clin Cancer Res. 2025 Oct 13. doi: 10.1158/1078-0432.CCR-25-2102.
   PubMed     Abstract available
   
   
   
8. BRIGHI N, Wetterskog D, Vainauskas O, Orlando F, et al
   Liquid biopsy identifies taxane resistance and clonal selection in castration-resistant prostate cancer.
   Clin Cancer Res. 2025 Oct 13. doi: 10.1158/1078-0432.CCR-25-2121.
   PubMed     Abstract available
   
   
   September 2025
9. BLINKA S, Yu EY
   Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.
   Clin Cancer Res. 2025 Sep 9. doi: 10.1158/1078-0432.CCR-25-2546.
   PubMed     Abstract available
   
   
   August 2025
10. OWIREDU J, Ersoy-Fazlioglu B, Poluben L, Calagua C, et al
    Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancer.
    Clin Cancer Res. 2025 Aug 12. doi: 10.1158/1078-0432.CCR-22-3683.
    PubMed     Abstract available
    
    
    
11. NAYAK S, Norris JD, Ammirante M, Rychak E, et al
    Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0471.
    PubMed     Abstract available
    
    
    
12. JIAO J, Ma S, Wu P, Song X, et al
    Transrectal Ultrasound-Guided Prostate Biopsy With and Without PSMA PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0320.
    PubMed     Abstract available
    
    
    July 2025
13. GRAHAM LS, Yu EY
    Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer.
    Clin Cancer Res. 2025 Jul 31. doi: 10.1158/1078-0432.CCR-25-2359.
    PubMed     Abstract available
    
    
    
14. AGGARWAL R, Rottey S, Bernard-Tessier A, Mellado B, et al
    Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
    Clin Cancer Res. 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1211.
    PubMed     Abstract available
    
    
    
15. MAGUIRE WF, Chi DC, Agrawal S, Joeng HK, et al
    FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Jul 17. doi: 10.1158/1078-0432.CCR-25-0883.
    PubMed     Abstract available
    
    
    
16. PATEL RB, Adler SS, Escorcia FE
    Size Matters: Superior Efficacy of alpha Particle Radioimmunotherapy in Micrometastases versus Macrometastases.
    Clin Cancer Res. 2025;31:2847-2849.
    PubMed     Abstract available
    
    
    
17. SHEN F, Smith R, McDevitt T, Menard K, et al
    Human kallikrein 2: A novel lineage-specific surface target in prostate cancer.
    Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-25-0950.
    PubMed     Abstract available
    
    
    June 2025
18. HAGE CHEHADE C, Graf RP, Ozay ZI, Gebrael G, et al
    Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.
    Clin Cancer Res. 2025 Jun 16. doi: 10.1158/1078-0432.CCR-25-1178.
    PubMed     Abstract available
    
    
    May 2025
19. DEV H, Linch M, Narahari K, Milne-Clark T, et al
    Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib +/- Degarelix in Primary Prostate Cancer.
    Clin Cancer Res. 2025 May 13:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-1304.
    PubMed     Abstract available
    
    
    
20. ARAFA AT, Yadav S, Marshall CH, Mauer E, et al
    Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.
    Clin Cancer Res. 2025;31:1730-1745.
    PubMed     Abstract available
    
    
    April 2025
21. WERNECK GOMES H, Lister NL, Keerthikumar S, Niranjan B, et al
    p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer.
    Clin Cancer Res. 2025 Apr 25. doi: 10.1158/1078-0432.CCR-24-3848.
    PubMed     Abstract available
    
    
    
22. SHAH K, Secrest MH, Zhou W, Wang S, et al
    Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
    Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1812.
    PubMed     Abstract available
    
    
    
23. KISHAN AU, McGreevy K, Valle L, Steinberg M, et al
    Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3951.
    PubMed     Abstract available
    
    
    March 2025
24. MCNEVIN CS, Keogh A, Mohammed Nur M, McGovern B, et al
    Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.
    Clin Cancer Res. 2025 Mar 19:OF1-OF8. doi: 10.1158/1078-0432.CCR-24-1210.
    PubMed     Abstract available
    
    
    
25. ZHANG L, Teng PC, Cavassani KA, Wang J, et al
    Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer.
    Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-3660.
    PubMed     Abstract available
    
    
    
26. HWANG J, Likasitwatanakul P, Deshmukh SK, Wu S, et al
    Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.
    Clin Cancer Res. 2025;31:936-948.
    PubMed     Abstract available
    
    
    February 2025
27. BJARTELL A, Krzyzanowska A, Liu VYT, Tierney M, et al
    Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy.
    Clin Cancer Res. 2025 Feb 21. doi: 10.1158/1078-0432.CCR-24-3656.
    PubMed     Abstract available
    
    
    
28. GALSKY MD, Autio KA, Cabanski CR, Wentzel K, et al
    Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693.
    PubMed     Abstract available
    
    
    
29. BIDKAR AP, Peter R, Wadhwa A, Bobba KN, et al
    Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
    Clin Cancer Res. 2025 Feb 13. doi: 10.1158/1078-0432.CCR-24-2850.
    PubMed     Abstract available
    
    
    January 2025
30. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed     Abstract available
    
    
    
31. ANDREWS J, Kim Y, Horjeti E, Arafa A, et al
    PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate Cancer Analysis from the STOMP-like and ORIOLE trial cohorts.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-3027.
    PubMed     Abstract available
    
    
    
32. WELTI J, Bogdan D, Figueiredo I, Coleman I, et al
    NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386.
    PubMed     Abstract available
    
    
    November 2024
33. HAFFNER MC, Morris MJ, Ding CC, Sayar E, et al
    Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2061.
    PubMed     Abstract available
    
    
    
34. WINQUIST E, Hotte SJ, Chi K, Sridhar S, et al
    Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612.
    PubMed     Abstract available
    
    
    
35. NAWFAL R, El Hajj Chehade R, Berchuck JE
    Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
    Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-2849.
    PubMed     Abstract available
    
    
    October 2024
36. STOPSACK KH, Vijai J, Conry M, Berchuck JE, et al
    Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.
    Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-2483.
    PubMed     Abstract available
    
    
    September 2024
37. ISAACSSON VELHO P, Bastos DA, Saint'ana PT, Rigatti B, et al
    Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.
    Clin Cancer Res. 2024 Sep 27. doi: 10.1158/1078-0432.CCR-24-1595.
    PubMed     Abstract available
    
    
    
38. CHOU J, Robinson TM, Egusa EA, Lodha R, et al
    Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-23-3785.
    PubMed     Abstract available
    
    
    
39. JENSEN JL, Bobek O, Chan ICC, Miller BC, et al
    Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
    Clin Cancer Res. 2024 Sep 17:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0803.
    PubMed     Abstract available
    
    
    
40. DALLOS MC, Obradovic AZ, McCann P, Chowdhury N, et al
    Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-0060.
    PubMed     Abstract available
    
    
    August 2024
41. CHAUHAN PS, Alahi I, Sinha S, Ledet EM, et al
    Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-1658.
    PubMed     Abstract available
    
    
    
42. HUSSAIN M, Kocherginsky M, Agarwal N, Adra N, et al
    Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
    Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-1402.
    PubMed     Abstract available
    
    
    
43. NGUYEN CB, Reimers MA, Perera C, Abida W, et al
    Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Clin Cancer Res. 2024;30:3200-3210.
    PubMed     Abstract available
    
    
    July 2024
44. SWEENEY CJ, Petry R, Xu C, Childress M, et al
    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-1096.
    PubMed     Abstract available
    
    
    
45. LENIS AT, Ravichandran V, Brown S, Alam SM, et al
    Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
    Clin Cancer Res. 2024 Jul 1. doi: 10.1158/1078-0432.CCR-23-3403.
    PubMed     Abstract available
    
    
    April 2024
46. APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al
    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
    PubMed     Abstract available
    
    
    
47. ARCHER S, Brailey PM, Song M, Bartlett PD, et al
    CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
    Clin Cancer Res. 2024;30:1595-1606.
    PubMed     Abstract available
    
    
    
48. SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al
    Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
    PubMed     Abstract available
    
    
    
49. CHO H, Byun SS, Son NH, Chung JI, et al
    Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083.
    PubMed     Abstract available
    
    
    March 2024
50. DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al
    A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
    PubMed     Abstract available
    
    
    
51. AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al
    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
    PubMed     Abstract available
    
    
    
52. ANSELMINO N, Labanca E, Shepherd PDA, Dong J, et al
    Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-23-2438.
    PubMed     Abstract available
    
    
    February 2024
53. VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al
    ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
    Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
    PubMed     Abstract available
    
    
    
54. DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al
    A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
    PubMed     Abstract available
    
    
    January 2024
55. HALABI S, Guo S, Park JJ, Nanus DM, et al
    The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017.
    PubMed     Abstract available
    
    
    
56. ABIDA W, Hahn AW, Shore N, Agarwal N, et al
    Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.
    Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508.
    PubMed     Abstract available
    
    
    September 2023
57. CHAUDAGAR K, Hieromnimon HM, Kelley A, Labadie B, et al
    Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
    Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.